These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 27322484)
1. News on the medical treatment of young women with early-stage HER2-negative breast cancer. Lambertini M; Poggio F; Vaglica M; Blondeaux E; Del Mastro L Expert Opin Pharmacother; 2016 Aug; 17(12):1643-55. PubMed ID: 27322484 [TBL] [Abstract][Full Text] [Related]
2. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173 [TBL] [Abstract][Full Text] [Related]
3. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Conte B; Poggio F; Del Mastro L Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603 [TBL] [Abstract][Full Text] [Related]
4. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. Sammons S; Sedrak MS; Kimmick GG Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240 [TBL] [Abstract][Full Text] [Related]
5. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan. Shimomura A; Sagara Y; Koto R; Fujiwara M; Kanemura Y; Kitagawa H; Saji S Breast Cancer; 2024 Jul; 31(4):581-592. PubMed ID: 38679657 [TBL] [Abstract][Full Text] [Related]
6. The curability of breast cancer and the treatment of advanced disease. Guarneri V; Conte PF Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948 [TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680 [TBL] [Abstract][Full Text] [Related]
10. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866 [TBL] [Abstract][Full Text] [Related]
11. Optimal adjuvant endocrine therapy for early breast cancer. Stuart-Harris R; Davis A Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605 [TBL] [Abstract][Full Text] [Related]
12. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Jankowitz RC; McGuire KP; Davidson NE Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781 [TBL] [Abstract][Full Text] [Related]
13. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary. Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy for premenopausal women: Type and duration. Francis PA Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713 [TBL] [Abstract][Full Text] [Related]
15. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Colozza M; de Azambuja E; Cardoso F; Bernard C; Piccart MJ Oncologist; 2006 Feb; 11(2):111-25. PubMed ID: 16476832 [TBL] [Abstract][Full Text] [Related]
16. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC]. Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789 [TBL] [Abstract][Full Text] [Related]
17. [Sensitivity of chemotherapy depending on hormone status in breast cancer]. Ito Y Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212 [No Abstract] [Full Text] [Related]
18. [Adjuvant chemotherapy of early stage breast cancer]. Boér K Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750 [TBL] [Abstract][Full Text] [Related]
19. Progress in systemic chemotherapy of primary breast cancer: an overview. Hortobagyi GN J Natl Cancer Inst Monogr; 2001; (30):72-9. PubMed ID: 11773296 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for premenopausal patients with early breast cancer. Kurebayashi J Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]